Answers are grounded in this paper and cite their sources.
Meeting abstracts As single agents, durvalumab (MEDI4736), a human IgG1 anti-PD-L1 antibody, and tremelimumab, a human IgG2 anti-CTLA-4 antibody, have shown acceptable safety profiles and antitumor activity. Similar to other anti-PD-L1/anti-PD-1 monotherapies, durvalumab has shown greater objective
No takes yet. Share an insight, caveat, or question.
Rizvi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: